[en] Ectopic acromegaly is a consequence of rare neuroendocrine tumors (NET) that secrete growth hormone releasing hormone (GHRH). This abnormal GHRH secretion drives growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess, with a clinical presentation similar to classical pituitary acromegaly. Identifying the underlying cause for the GH hypersecretion in the setting of ectopic GHRH excess is, however, essential for proper management both of acromegaly and the NET. Owing to its rarity, the imaging characteristics of the pituitary in ectopic acromegaly have not been analyzed in depth in large series.Characterize pituitary magnetic resonance imaging (MRI) features at baseline and after NET treatment in patients with ectopic acromegaly.Multicenter, international, retrospectiveTertiary referral pituitary centers30 ectopic acromegaly patients due to GHRH hypersecretionNoneMRI characteristics of pituitary gland, particularly T2-weighted signalIn 30 patients with ectopic GHRH-induced acromegaly, we found that most patients had hyperplastic pituitaries. Hyperplasia was usually moderate but was occasionally subtle, with only small volume increases compared to normal ranges for age and sex. T2-weighted signal was hypointense in most patients, especially in those with hyperplastic pituitaries. After treatment of the NET, pituitary size diminished and T2-weighted signal tended to normalize.This comprehensive study of pituitary MRI characteristics in ectopic acromegaly underlines the utility of performing T2-weighted sequences in the MRI evaluation of patients with acromegaly as an additional tool that can help to establish the correct diagnosis.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
NECHIFOR - POTORAC, Iulia ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
BONNEVILLE, Jean-François ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic
Daly, Adrian ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
de Herder, Wouter
Fainstein-Day, Patricia
Chanson, Philippe
Korbonits, Marta
Cordido, Fernando
Lamback, Elisa Baranski
Abid, Mohamed
Raverot, Véronique
Raverot, Gerald
Anda Apiñániz, Emma
Caron, Philippe
Du Boullay, Helene
Bildingmaier, Martin
Bolanowski, Marek
Laloi-Michelin, Marie
Borson-Chazot, Francoise
Chabre, Olivier
Christin-Maitre, Sophie
Briet, Claire
Diaz-Soto, Gonzalo
Bonneville, Fabrice
Castinetti, Frederic
Gadelha, Mônica R
Santana, Nathalie Oliveira
Stelmachowska-Banaś, Maria
Gudbjartsson, Tomas
Villar-Taibo, Roció
Zornitzki, Taiba
TSHIBANDA, Luaba ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic
PETROSSIANS, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
BECKERS, Albert ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
Daly AF, Beckers A. The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am. 2020; 49(3):347-355. Doi: 10.1016/j.ecl.2020.04.002
Asa SL, Scheithauer BW, Bilbao JM, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab. 1984; 58(5):796-803. Doi: 10.1210/jcem-58-5-796
Ghazi AA, Amirbaigloo A, Dezfooli AA, et al. Ectopic acromegaly due to growth hormone releasing hormone. Endocrine. 2013; 43(2):293-302. Doi: 10.1007/s12020-012-9790-0
Potorac I, Petrossians P, Daly AF, et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer. 2015; 22(2):169-177. Doi: 10.1530/ERC-14-0305
Potorac I, Petrossians P, Daly AF, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer. 2016; 23(11):871-881. Doi: 10.1530/ERC-16-0356
Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012; 77(1):72-78. Doi: 10.1111/j.1365-2265.2011.04286.x
Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. 2016; 52(2):333-343. Doi: 10.1007/s12020-015-0766-8
Girard P, Cohen R, Sassolas G, Harthe C, Cabrera P, Boissel JP. Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses. Eur J Clin Pharmacol. 1987; 32(5):507-513. Doi: 10.1007/BF00637679
Schopohl J, Lose M, Frey C, et al. Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma. Clin Endocrinol (Oxf). 1991; 34(6):463-467. Doi: 10.1111/j.1365-2265.1991.tb00326.x
Tsunoda A, Okuda O, Sato K. MR height of the pituitary gland as a function of age and sex: Especially physiological hypertrophy in adolescence and in climacterium. Am J Neuroradiol. 1997; 18(3):551-554.
Yadav P, Singhal S, Chauhan S, Harit S. MRI evaluation of size and shape of normal pituitary gland: age and sex related changes. J Clin Diagnostic Res. 2017; 11(12):TC01-TC04. Doi: 10.7860/ JCDR/2017/31034.10933
R Core Team. R Core Team (2014). R: A Language and Environment for Statistical Computing. Vienna, AT: R Found. Stat. Comput. 2014. http//www.R-project.org/
Garby L, Caron P, Claustrat F, et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab. 2012; 97(6):2093-2104. Doi: 10.1210/jc.2011-2930
Fainstein Day P, Frohman L, Rivello HG, et al. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary. 2007; 10(3):311-319. Doi: 10.1007/s11102-007-0019-9
Álvaro JR, Arribas JJP, Apinániz EA, García LP, Tejedor JL, Llenas LF. Ectopic acromegaly due to a bronchial carcinoid. An Sist Sanit Navar. 2013; 36(3):563-567. Doi: 10.4321/ s1137-66272013000300022
Kałuzny M, Polowczyk B, Bladowska J, Kubicka E, Bidlingmaier M, Bolanowski M. Acromegaly due to ectopic growth hormonereleasing hormone secretion by lung carcinoid. Polish Arch Intern Med. 2020; 130(7-8):685-687. Doi: 10.20452/pamw.15337
Mnif Feki M, Mnif F, Kamoun M, et al. Ectopic secretion of GHRH by a pancreatic neuroendocrine tumor associated with an empty sella. Ann Endocrinol (Paris). 2011; 72(6):522-525. Doi: 10.1016/j. ando.2011.06.002
Zornitzki T, Rubinfeld H, Lysyy L, et al. pNET co-secreting GHRH and calcitonin: ex vivo hormonal studies in human pituitary cells. Endocrinol Diabetes Metab Case Rep. 2016; 2016(1). Doi: 10.1530/edm-15-0134
Chanson P. Acromégalie. Presse Medicale. 2009; 38(1):92-102. Doi: 10.1016/j.lpm.2008.09.016
Gudbjartsson T, Agnarsson BA, Palsson PS, Johannesson A. Acromegaly caused by ectopic growth hormone-releasing hormone production from a bronchial carcinoid tumor. Thorac Cardiovasc Surg. 2011; 59(3):184-185. Doi: 10.1055/s-0030-1250341
Van Hoek M, Hofland LJ, De Rijke YB, et al. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. J Clin Endocrinol Metab. 2009; 94(2):428-433. Doi: 10.1210/jc.2008-1712
Stelmachowska-Banaś M, Głogowski M, Vasiljevic A, Raverot V, Raverot G, Zgliczyński W. Ectopic acromegaly due to growth hormone-releasing hormone secretion from bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency. Pol Arch Intern Med. 2019; 129(3):208-210. Doi: 10.20452/pamw.4413
Lamback EB, Henriques DG, Vazquez-Borrego MC, et al. Growth hormone-releasing hormone-secreting pulmonary neuroendocrine tumor associated with pituitary hyperplasia and somatotropinoma. Arch Endocrinol Metab. 2021; 65(5):648-663. Doi: 10.20945/2359-3997000000395
Srirangam Nadhamuni V, Iacovazzo D, Evanson J, et al. GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1. Endocrinol Diabetes Metab Case Rep. 2021; 2021(1). Doi: 10.1530/edm-20-0208
Petrossians P, Daly AF, Natchev E, et al. Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocr Relat Cancer. 2017; 24(10):505-518. Doi: 10.1530/ERC-17-0253
Villa C, Lagonigro MS, Magri F, et al. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocr Relat Cancer. 2011; 18(3):347-356. Doi: 10.1530/ERC-11-0059
Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology. 2003; 228(2):533-538. Doi: 10.1148/radiol.2282020695
Puig-Domingo M, Resmini E, Gomez-Anson B, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010; 95(11):4973-4978. Doi: 10.1210/jc.2010-0573
Boix E, Picó A, Pinedo R, Aranda I, Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf). 2002; 57(1):131-134. Doi: 10.1046/j.1365-2265.2002.01535.x